CareDx (NASDAQ:CDNA) Issues Quarterly Earnings Results, Beats Expectations By $1.46 EPS

CareDx (NASDAQ:CDNA) issued its quarterly earnings results on Wednesday. The company reported $1.51 EPS for the quarter, beating analysts’ consensus estimates of $0.05 by $1.46, Zacks reports. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The company had revenue of $86.58 million for the quarter, compared to analyst estimates of $84.56 million.

CareDx Stock Performance

Shares of CDNA opened at $22.00 on Thursday. The stock has a market capitalization of $1.18 billion, a price-to-earnings ratio of -8.14 and a beta of 1.87. CareDx has a 52 week low of $7.42 and a 52 week high of $34.84. The stock has a fifty day moving average of $22.64 and a 200-day moving average of $25.32.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on CDNA. StockNews.com raised shares of CareDx from a “hold” rating to a “buy” rating in a research report on Wednesday. BTIG Research dropped their price target on CareDx from $40.00 to $35.00 and set a “buy” rating for the company in a report on Tuesday, November 5th. Wells Fargo & Company raised shares of CareDx from an “underweight” rating to an “equal weight” rating and reduced their target price for the company from $28.00 to $24.00 in a research report on Wednesday, January 15th. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $26.00 price target on shares of CareDx in a research report on Tuesday, January 14th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $28.33.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.